NCT04142229 is a NA clinical trial of iAPS in Type 1 Diabetes, sponsored by Sansum Diabetes Research Institute.

Who is sponsoring NCT04142229?

NCT04142229 is sponsored by Sansum Diabetes Research Institute.

What drugs are being tested in NCT04142229?

Interventions in NCT04142229: iAPS, Sensor-Augmented Pump.

What condition does NCT04142229 study?

NCT04142229 studies Type 1 Diabetes.

Is NCT04142229 still recruiting?

NCT04142229 is currently completed. Last updated 1 December 2020.

Last reviewed 2020-12-01 · How we verify

NCT04142229

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Artificial Pancreas With Different Stress Assessments in the Outpatient Setting

Completed NA Last updated 1 December 2020

What this trial tests

NA trial testing iAPS in Type 1 Diabetes in 14 participants. Completed in 6 November 2020.

Timeline

25 October 2019

Primary endpoint
6 November 2020

6 November 2020

Quick facts

Lead sponsor	Sansum Diabetes Research Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	25 October 2019
Primary completion	6 November 2020
Estimated completion	6 November 2020
Sites	2 locations across United States

Drugs / interventions tested

iAPS
Sensor-Augmented Pump

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

Sansum Diabetes Research Institute

Who can join

18 and older, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This feasibility study is a randomized crossover trial that will compare the efficacy and safety of an automated insulin delivery (AID) system in patients with type 1 diabetes using a Model Predictive Control (MPC) algorithm versus sensor augmented pump therapy (SAP)/Predictive Low Glucose Suspend (PLGS), and will include different stress induction and assessments over a 4 week period.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Use of the Interoperable Artificial Pancreas System for Type 1 Diabetes Management During Psychological Stress.
Pinsker JE, Deshpande S, McCrady-Spitzer S, Church MM, et al · · 2021 · cited 5× · PMID 32783473 · DOI 10.1177/1932296820948566
Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges.
Kaur RJ, Deshpande S, Pinsker JE, Gilliam WP, et al · · 2022 · cited 4× · PMID 35049354 · DOI 10.1089/dia.2021.0436
Glucose Rate-of-Change and Insulin-on-Board Jointly Weighted Zone Model Predictive Control.
Deshpande S, Doyle FJ, Dassau E. · · 2023 · cited 1× · PMID 38525198 · DOI 10.1109/tcst.2023.3291573

Verify or expand the search:

Other trials of iAPS

Trials testing the same drug.

NCT03767790 — Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) · NA · completed

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other Sansum Diabetes Research Institute trials

Trials by the same sponsor.

NCT06218147 — Community-Based Nutrition-Lifestyle Therapy for Pregnant Latina Women With Diabetes · NA · completed
NCT05975242 — Acceptability & Impact of a Diabetes Management Smartphone App (mySugr) for Spanish-literate Adults With Type 2 Diabetes · NA · completed
NCT05293340 — Continuous Glucose Monitoring and Hass Avocado Trial ("CHAT") · NA · terminated
NCT04938388 — Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care · Phase 4 · terminated
NCT05000840 — Integrating Abbott Point-of-Care Technologies and the Community Scientist Model to Support HbA1c Testing Per ADA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04142229 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sansum Diabetes Research Institute
Last refreshed: 1 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04142229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing